An Observational Study of Patients With Dermatologic Disease

NCT07748169 | Recruiting

• 1 other identifier: TARGET-DERM+
• Study Type: observational
• Target: 2,000,000
• Locations: 1 country
• Sites: 3

Brief Summary

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Conditions

Atopic Dermatitis; Alopecia Areata; Vitiligo; Hidradenitis Suppurativa (HS)

Keywords

Dermatologic Disease; DERM+

Outcome Measures

Primary Outcomes (3)

• To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease

  The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD

  15 years

• To characterize the natural history of disease in patients with dermatologic disease from various etiologies

  A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.

  15 years

• To establish learning health networks focused on quality of care for patients

  Identify deficiencies and best practices in care of patients with DD. • Evaluate outcomes from targeted learning content in the management of patients with DD.

  15 years

Secondary Outcomes (2)

• To evaluate provider management practices in the treatment of patients with DD

  15 years

• To evaluate longitudinal and patient reported outcomes in DD

  15 years

Study Arms (2)

Disease Cohort

Adult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface.

Engaged Cohort

Adult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions. * Informed consent is required for all participants in an Engaged Cohort. * Willing to complete required Engaged Cohort activities.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

2,000,000

You may qualify if:

• Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
• Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.

You may not qualify if:

• Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Sponsors & Collaborators

• Target PharmaSolutions, Inc.: lead

Study Sites (3)

Wake Forest University Health Science

Winston-Salem, North Carolina, 27157, United States

RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

Medical University of South Carolina

Charleston, South Carolina, 29407, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood or saliva specimens may be used as a source of germline DNA for genetic analyses. Serum biospecimens can be used for research purposes to identify potential biomarkers predictive of disease diagnosis, assess correlation of response to treatment (in terms of mode action, effectiveness, dose, safety, and tolerability), understand factors influencing disease progression, determine how best to monitor and treat disease, aid in the development of a new medical products, or explore complications of the disease and treatment. Once collected, biospecimens may be shipped to a central repository and stored indefinitely.

MeSH Terms

Conditions

Vitiligo; Dermatitis, Atopic; Alopecia Areata; Hidradenitis Suppurativa; Skin Diseases

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin and Connective Tissue Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration; Hidradenitis; Sweat Gland Diseases

Study Officials

• Laura Dalfonso

  Pedestal Health

  STUDY DIRECTOR

Central Study Contacts

Lynda Lee Burch

CONTACT

9842340268; lburch@pedestalhealth.com

Danisha Devane

CONTACT

9842340268; ddevane@pedestalhealth.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 15 Years
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2026
• First Posted: August 5, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): August 3, 2041
• Study Completion (Estimated): August 3, 2041
• Last Updated: August 5, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)